Cardea Bio

Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors. Cardean transistors leverage biocompatible graphene instead of silicon and replace optical signal observations with direct electrical molecular signal analysis. With Cardean transistors, the company and its Innovation Partners can generate streaming multi-omics data to measure real-time biological signals. Cardea is now manufacturing chips at scale and partners have started to significantly expand the amount, type, and quality of biological data they capture by building products that Conduct Biolog.

Cardea Bio headquartered in United States, North America, operates in the Information Technology, Semiconductor, Biotechnology, Manufacturing sector. The company focuses on Information Technology and has secured $2.7B in funding across 112 round(s). With a team of 11-50 employees, Cardea Bio is actively contributing to advancements in Information Technology. Their latest funding round, Grant - Cardea Bio, raised $1.1M. Discover more about their projects, partnerships, and impact on our platform.